Brought to you by 
Thermalin launches $17.5mm Series A round
02 Oct 2017
Executive Summary
Thermalin Inc. (formerly Thermalin Diabetes LLC) closed the initial tranche of a $17.5mm Series A round, which Strategic Transactions assumes follows a recapitalization by the company. New strategic partner Sanofi participated along with JSP-mbIVC LifeScience Investment Ltd. Partnership, Green Park & Golf Ventures, and other existing investors. Formed in 2010, preclinical-stage Thermalin is developing engineered insulin analogs, including ultra-rapid-acting insulin, glucose-responsive insulin, a once-a-week insulin patch, and insulin that doesn't need refrigeration. The company completed previous venture rounds, including a Series B in 2014 that it stated had brought in $5.9mm.
Deal Industry
- Medical Devices
- Pharmaceuticals
-
Biotechnology
- Large Molecule
Deal Status
- Final
Deal Type
-
Financing
- Venture Financing
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Thermalin launches $17.5mm Series A round
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice